JDNPPA is the only independent, omni-channel resource that is for dermatology NPs and PAs and by NPs and PAs.
Joined March 2024
- Tweets965
- Following294
- Followers41
- Likes1.1K
Pinned Tweet
Join Leigh Ann Pansch, MSN, FNP-BC, DCNP, for a discussion on earlier intervention with #COSENTYX® (secukinumab). *Bonus: Stay for a session on social media engagement with Steven Daveluy, MD! REGISTER HERE: inceptionmeetings.com/Dermat…
JDNPPA retweeted
#Dermatology PA, Kara Mudd, DMSc, MSPAS, PA-C shares more about her role on the Advisory Council for Maui Derm, and gives insight into why PAs and NPs should join her at the next #MauiDerm meeting in Summer 2027!
JDNPPA retweeted
The US FDA approved remibrutinib (#Rhapsido, @NovartisCT) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. jdnppa.com/us-fda-approves-f…
[NEW ISSUE] In advance of #WorldPsoriasisDay, our newest cover story explores how #dermatology & #rheumatology advanced practice providers can collaborate to optimize outcomes for patients with psoriatic disease. #WeekendRead digitaleditions.walsworth.co…
JDNPPA retweeted
The advent of novel non-steroidal targeted topicals, including ruxolitinib cream, have expanded the therapeutic toolbox, providing more options for #atopicdermatitis patients who don’t want to or can’t use topical corticosteroids. tdd.mydigitalpublication.com…
JDNPPA retweeted
Oral icotrokinra (#Icotyde, JNJ) produces durable skin clearance on high-impact #plaquepsoriasis (PsO) sites, new research shows. jdnppa.com/oral-icotrokinra-…
JDNPPA retweeted
Oral Janus kinase (JAK) inhibitors should be first-line therapy for adults with severe #alopecia areata, according to the first-ever standardized treatment recommendations for these patients. jdnppa.com/its-time-to-rethi…
Infants born to mothers who ate a healthy, Mediterranean-style diet during pregnancy were at lower risk for colic and #eczema, according to a new study in @JAMANetworkOpen. jdnppa.com/can-eating-a-heal…
JDNPPA retweeted
The US FDA has approved pritelivir (#Hovilpri, Asahi Kasei Therapeutics) tablets for immunocompromised adults with mucocutaneous lesions caused by #herpessimplex virus (#HSV) infection who have not responded to treatment with acyclovir, valacyclovir, or famciclovir. thedermdigest.com/us-fda-app…
#Dermatology PA, Kara Mudd, DMSc, MSPAS, PA-C shares more about her role on the Advisory Council for Maui Derm, and gives insight into why PAs and NPs should join her at the next #MauiDerm meeting in Summer 2027!
JDNPPA retweeted
The last two episodes in our roundtable series are now available! 📺 Check them out or catch up on all eight episodes released this month! jdnppa.com/videos/refining-t…
JDNPPA retweeted
🆕 🆕 🆕 This broadcast will explore the science behind Cloud-Tech™ & how the Neutrogena® formulation expertise helps optimize both protection & wearability, supporting the features patients want in a daily sunscreen. Register: inceptionmeetings.com/Dermat…
JDNPPA retweeted
From identifying appropriate candidates for #GLP1 RAs to recognizing potential dermatologic complications associated with their use, Laura Bush DMSc, PA-C, DFAAPA, shares practical insights on using these agents in patients with #skindisease and obesity. jdnppa.com/what-every-dermat…
The US FDA approved remibrutinib (#Rhapsido, @NovartisCT) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. jdnppa.com/us-fda-approves-f…
JDNPPA retweeted
Our latest supplement presents summaries of reports on #sarecycline along with clinician commentaries that help apply the findings to patient care. tdd.mydigitalpublication.com…
The advent of novel non-steroidal targeted topicals, including ruxolitinib cream, have expanded the therapeutic toolbox, providing more options for #atopicdermatitis patients who don’t want to or can’t use topical corticosteroids. tdd.mydigitalpublication.com…
Oral icotrokinra (#Icotyde, JNJ) produces durable skin clearance on high-impact #plaquepsoriasis (PsO) sites, new research shows. jdnppa.com/oral-icotrokinra-…
JDNPPA retweeted
US FDA approves remibrutinib (Rhapsido, @Novartis) for adults with symptomatic #dermographism (SD) inadequately controlled by H1 antihistamines. Remibrutinib, an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), is the first and only treatment for adults with SD. thedermdigest.com/breaking-u…
PAs advocate for patients, break down barriers to care, and stand up for communities who need a voice. This #PAweek, and all year long, we recognize and applaud this commitment! #PAsGoBeyond @AAPAorg
